Stunning Start For Vertex Cystic Fibrosis Triple Combo
Trikafta Shatters Forecasts With Q4 $420m Sales
Only nine weeks after US approval, Trikafta, which in theory can treat 90% of all patients with cystic fibrosis, is already Vertex's top-selling medicine.
You may also be interested in...
While Vertex appears to have the cystic fibrosis market covered with its CFTR modulators, Enterprise has been exploring another channel, TMEM16A, in the hope of developing compounds that could possibly be used by everybody with the lethal genetic disease.
EU approval came quicker than expected for Vertex’s new triple-combination CFTR drug, Kaftrio.
After a long-standing row with payer NHS England, the rapid market access deal will help Vertex move into growth phase.